APRE News and Press, Aprea Therapeutics Inc. From 08/11/20

Aprea Therapeutics (NASDAQ: APRE ) : Q2 GAAP EPS of -$0.78 misses by $0.19 . More news on: Aprea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three and si...

Aprea Therapeutics ( APRE ) is a clinical stage biotechnology company with a promising cancer drug that is in a Phase 3 study that should report out preliminary data late in 2020. If the drug, eprenetapopt, shows positive results, it could get approved by regulatory agencies and, with further ...

Aprea Therapeutics (NASDAQ: APRE )   expands patient enrollment in its Phase 1 trial evaluating eprenetapopt, in TP53 mutant acute myeloid leukemia (AML). More news on: Aprea Therapeutics, Inc., Healthcare stocks news, Read more ...

Commenced expansion cohort in combination with venetoclax and azacitidine Added cohort to be activated in combination with azacitidine BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercia...

Stocks in the biotechnology sector have outperformed the broader market year to date. Despite the market volatility throughout this year, there are still good prospects in this sector, especially in small-ca p biotechnology stocks. These companies are often selling at attractive prices, and the...

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointments of Fouad Namoun...

Aprea Therapeutics (NASDAQ: APRE )  announces updated results from a Phase 1/2 clinical trial evaluating lead candidate APR-246 (eprenetapopt), combined with chemo agent azacitidine, in patients with TP53 mutation-positive myelodysplastic syndromes (MDS) or TP53 mutation-positive acu...

57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS in patients receiving 3 or more cycles of therapy with 9.7 months duration of follow-up ...

Investing in biotech stocks focused on experimental oncological therapies is risky enough. What's even more perilous is buying a biotech stock that will make or break on one such candidate alone. Indeed, the probability that an experimental candidate can progress from phase 1 to approval stands ...